Novavax
NVAX
202 hedge funds and large institutions have $371M invested in Novavax in 2024 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 73 increasing their positions, 43 reducing their positions, and 28 closing their positions.
125% more call options, than puts
Call options by funds: $214M | Put options by funds: $94.8M
70% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 43
14% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 28
1% more funds holding
Funds holding: 200 → 202 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $376M → $371M (-$4.65M)
10.55% less ownership
Funds ownership: 65.5% → 54.96% (-11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$5.25M |
| 2 |
BlackRock
New York
|
+$4.6M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.59M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
+$3.87M |
| 5 |
Citigroup
New York
|
+$2.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$24.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.95M |
| 3 |
Jane Street
New York
|
-$4.66M |
| 4 |
Barclays
London,
United Kingdom
|
-$2.64M |
| 5 |
Millennium Management
New York
|
-$1.83M |
NVAX Hedge Fund Activity: Q1 2024 in Review
202 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q1 2024, worth a combined $371M — down 1.2% from $376M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new NVAX positions and 28 closed out — a net gain of 4 holders — while 73 added to existing stakes and 43 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $5.25M. The largest seller was Morgan Stanley, cutting an estimated $24.9M.
- 202 institutional investors held Novavax (NVAX) as of Q1 2024, up from 200 in Q4 2023.
- Funds reported $371M of Novavax stock for Q1 2024, down 1.2% quarter-over-quarter.
- 32 funds opened new Novavax positions in Q1 2024 and 28 closed out, a net change of +4 holders.
- The largest Novavax buyer in Q1 2024 was Farallon Capital Management, an estimated $5.25M added.
- The largest Novavax seller in Q1 2024 was Morgan Stanley, an estimated $24.9M sold.
Based on aggregated 13F filings for Q1 2024.